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Abstract 
Although stereotactic radiosurgery (SRS) is an effective modality in the treatment of brainstem 
metastases (BSM), radiation induced toxicity remains a critical concern. To better understand 
how severe or life-threatening toxicity is affected by the location of lesions treated in the 
brainstem, a review of all available studies reporting SRS treatment for BSM was performed. 
Twenty-nine retrospective studies investigating SRS to BSM were reviewed. The rates of grade 3 
or greater toxicity, based on the Common Terminology Criteria for Adverse Events varied from 
0-9.5% (mean 3.4% ± 2.9%). Overall, the median time to toxicity after SRS was 3 months, with 
90% of toxicities occurring before 9 months. A total of 1243 cases had toxicity and location data 
available. Toxicity rates for lesions located in the medulla were 0.8% (1/131), compared to 
midbrain and pons respectively, 2.8% (8/288) and 3.0% (24/811).  Current data suggests that 
brainstem substructure location does not predict for toxicity and lesion volume within this cohort 
with median tumor volumes 0.04-2.8 cc does not predict for toxicity. 
Introduction 
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Stereotactic radiosurgery (SRS) for brainstem metastases (BSM) has been shown to be a 
safe and effective modality 1-31. Reported rates of local tumor control in patients who received 
SRS for BSM vary from 74-100% and the median survival ranges from 4-12 months 1-28,30-32. 
Despite the promising results of SRS with respect to local control and survival, toxicity due to 
radiation is always a concern, with severe to life threatening toxicities being reported in 0-9.5% 
of patients with BSM treated with SRS 2-10,12-14,16-18,20-28,30-32. Majority of papers have not 
analyzed the impact of location on toxicity or volume of lesions on toxicity 2-10,12-14,16-18,20-28,30-32. 
Due to a relatively small sample size, the preferred dose to treat BSM remains controversial with 
literature varying on the dosing strategies 2-10,12-14,16-18,20-28,30-32. This review paper aims to 
synthesize the collective literature available on SRS to BSM.  
Methods 
In order to identify brainstem location specific toxicity after SRS “Brainstem metastases 
radiosurgery,” was searched as a keyword in PubMed and Ovid (MEDLINE). Primary literature 
specific to treatment of BSM with SRS was reviewed. Only retrospective studies of patients 
treated with SRS for BSM were available; (shown in Figure 1). This literature review does not 
include brainstem metastases that are described in larger non-brainstem studies. Some authors 
were contacted for the details regarding the reported toxicities 2,15,30 Of the two Trifiletti papers 
including the institutional and international papers, only the data from the institutional paper, 
which provided the pertinent information, was used for the location based toxicity analysis in 
order to avoid duplicate inclusion of cases 22,23. All the remainder of papers were included with 
no obvious concern for duplication in reported cases. For one report that did not specify the 
number of lesions per patient, the number of lesions were assumed to be equal to the number of 
patients for the purposes of this review (n=41) 18.  
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The following data were collected from each manuscript: method of SRS, total number of 
patients, total number of lesions, locations of lesions, median or mean age, median or mean 
Karnofsky Performance Status (KPS), median or mean prescription dose (most reports included 
only margin dose information and prescription isodose information was often not available), 
number of patients who received whole brain radiation therapy (WBRT), mean or median 
survival after SRS, local tumor control rate, radiation induced toxicity, and mean or median 
tumor volume. The mean rate of local control, toxicity, and WBRT were calculated based on 
values in all reports. 
For this analysis, only toxicities of grade 3 or greater were included in this review 33. Not 
all reports explicitly stated whether the toxicity was grade 3 or greater based on the Common 
Terminology Criteria for Adverse Events, but it was inferred based on the description of toxicity 
and treatment if it could be classified as grade 3 or greater. For example, if a manuscript 
described a case of toxicity where radionecrosis was refractory to steroids than this was counted 
as a toxicity ≥ grade 3. The details of the grading of toxicity are presented in Table 1. Grade 2 
toxicity could not be reviewed because there was no specification on exactly how many patients 
developed grade 2 toxicities in manuscripts. There were two Trifiletti paper that could have 
obscured the data, care was taken to avoid this. In one instance, the institutional data was 
removed to tabulate the occurrence of metastases in the substructures and in the other instance 
the international paper by Trifiletti et al. was removed because it did not report both location and 
toxicity. This was clarified by the authors of the paper as well.  
The following variables were included when tabulating the toxicities, to the extent 
available: gender, age, primary cancer histology, location of treated lesion, volume of tumor, 
dosage of SRS, whether WBRT was given or not, the type of toxicity, time to toxicity from SRS 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
treatment, and status of local control. An unpaired t-test was used to compare the means of the 
volumes of the lesions with toxicity and those without toxicity.  
Results 
The searches identified twenty-nine retrospective studies of BSM treated with SRS published 
from 1999-2017. The details of these reports are summarized in Table 2, listed chronologically 
and by first author. SRS modalities reported include Gamma Knife (GK), LINAC (Linear 
Accelerator), and Cyber Knife (CK). A total of 2037 SRS treated metastases were reported in 
1878 patients. The median age ranged from 50-69 years old and the mean age ranged from 52.9-
64 years old. The median KPS ranged from 70-90.  
1) Summary of Literature 
Out of 29 reports 26 specified the locations of the lesions. One report did not account for the 
location of 8 out of 52 lesions and two other reports did not comment on the location of BSM 
9,10,18
. This resulted in a total of 1945 lesions with the location of the BSM specified; the most 
common location was the pons, representing 62.8% (1222/1945) of the cases; the midbrain was 
the next most common, representing 22.4% (436/1945) of cases; and 9.6% (186/1945) of cases 
were found in the medulla. Other structures represented 5.2% of cases; the pontomesencephalic 
junction accounted for 2.7% (52/1945) of cases, the pontomedullary junction accounted for 1.4% 
(27/1945) of cases and the cerebellopontine angle (CPA) that extended into brainstem proper 
accounted for 1.2% (24/1945) of cases. Removing the institutional report by Trifiletti, to avoid 
accounting for some patients twice, resulted in 22.8% (400/1756) of cases in the midbrain, 
62.2% (1093/1756) in the pons, 9.8% (172/1756) in the medulla, and the other 5.2% in junctions 
among the substructures of the brainstem 23.  
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The radiosurgery characteristics were as follows. The median prescription dose ranged 
between 13-18 Gy. WBRT prior to or after SRS ranged from 6.5% - 96.4% with the mean being 
48.4±19.8%. The local control rate at 12 months varied from 74-100%. The median overall 
survival ranged from 3.9-17.2 months. The local control rate at 12 months based on the mean of 
all the reported values in literature turned out to be 86.7% ± 5.9%, all but one manuscript 
reported local control rates at 12 months 12. Removing the institutional Trifiletti study resulted in 
less than 1% variation in the mean of the local control rate 23. The median tumor volume ranged 
from 0.04-2.8 cc and the mean tumor volume ranged from 0.7-2.8 cc.  
2) Toxicity  
A total of 2037 cases were reviewed; 58 were excluded for lack of comments on toxicity 1,19. 
A total of 79 patients were reported in the literature to have suffered from toxicity out of 1979 
potential cases.  Rate of toxicity reported in patients treated with SRS for BSM varied from 0-
9.5%. The average rate of toxicity based on reported percentages per report was 3.4% ± 2.9%.  
To analyze location based toxicity 1979 cases reviewed, 84 were excluded because there was 
no comment on location 10,18 and 644 were excluded for lack of location associated with toxicity 
17,22
. This resulted in 1251 cases that commented on both location and toxicity. It is imperative to 
note that this exclusion accounted for any potential overlap between the Trifiletti studies and 
only the institutional one was used for the location-based toxicity analysis 22,23. In the studies 
which contained locations of toxicities, 23.0% (288/1251) of all treated BSM were in the 
midbrain, 64.8% (811/1251) in the pons, and 10.5% (131/1251) in the medulla. An additional 
eight lesions did not account for the location in one report and the other 1% of lesions were 
either in the CPA or midbrain pons junction 9. The rates of grade 3 or greater toxicity associated 
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with treatments to metastases in the midbrain, pons, and medulla were 2.8% (8/288), 3.0% 
(24/811), and 0.8% (1/131) respectively.  
To compare treatment and tumor characteristics amongst the substructures, seven reports 
were examined that commented on both toxicity and location, with patient level data available 
for 260 cases (of 1251 possible) 6,15-17,21,28,31. One report was missing tumor volume data for 3 
lesions 6. A total of 30 patients had metastases that were treated in the medulla. The median 
volume was 0.5 cc (mean 1.1 cc, range 0.01-12.2 cc). The median prescription dose was 16 Gy 
(mean 16.8 Gy, range 10-24 Gy). In the midbrain, 56 cases were reported with 16 Gy as the 
median prescription dose (mean 16.7 Gy, range 8-24 Gy) and 0.3 cc as the median volume (mean 
0.8 cc, range 0.01-6.1 cc). In the pons, 174 cases were available with a median prescription dose 
of 16 Gy (mean 16.3 Gy, range 8-24 Gy) and a median volume of 0.3 cc (mean 1.2 cc, range 
0.004-12 cc), suggesting that treatments and lesions were similar among the brainstem 
substructures in the subset of patients with available data.  
To compare the volumes of the lesions with and without toxicity the same seven reports from 
the previous paragraph were used. This resulted in 260 possible patients that could be analyzed 
based on patient level data available and development of toxicity 6,15-17,21,28,31. For the lesions that 
developed toxicity (n=10) this resulted in a mean volume of 1.6 ± 1.0 cc. For the rest of the 
patients in the reports (n-247) the mean volume was 1.1 ± 1.2 cc. The two-tailed P value equals 
0.2 for the comparison of these two means.  
The reported 79 cases with toxicity were reviewed to summarize patient and treatment 
factors potentially associated with toxicity. Only 35 of the 79 toxicity cases reported in the 
literature were described in more detail 2,4,6-9,13,14,17,18,21,23,25,27,28,30. The details of the 35 cases are 
summarized in Table 3. In this toxicity cohort, 22.8% of cases were in the midbrain, 68.6% in the 
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pons, 2.9% in the medulla, and 5.7% did not have a location reported. All reported toxicities 
occurred before 18 months and with a median time to toxicity of 3.0 months. The median 
prescription dose was 15 Gy for midbrain cases and 16.3 Gy for pons cases. Midbrain BSM had 
a median volume of 0.9 cc (range: 0.1-3.3 cc) and pons cases a median volume of 1.3 cc (range: 
0.1-5.8 cc). 
Discussion 
Radiosurgery has consistently been proven to be a safe and effective treatment for BSM, 
yet toxicity remains a concern for both the patient and physician1-28,30,32. The last review article 
that addressed clinical outcomes after SRS for BSM was published in 2013 and synthesized 12 
reports 11. Based on limited number of cases in previously published reports about BSM, it has 
been difficult to synthesize data and comment on the treatment preferences for BSM and other 
characteristics that influence toxicity rates. Thus, a review of the available literature was 
performed to comment on the varying doses used in the literature and analyze the rate of 
radiation induced toxicities with respect to different locations in the brainstem and volume. Table 
2 shows that the most common site of BSM is unequivocally the pons. The median prescription 
dose varied from 13-18 Gy. The mean local control rate was 86.7 ± 5.9% with the rate of toxicity 
being 3.4 ± 2.9%.  
Interestingly, the median time to development of toxicity from SRS to BSM was 3 
months with greater than 90% occurrence before 9 months. In contrast, lesions in the cerebral 
parenchyma exhibited median time to toxicity at 4.5 months (range 0.5-36.0 months) in 
randomized controlled trials (RCT) 34. In another RCT evaluating the combination of SRS and 
WBRT for brain metastases in which 9% of the patients developed toxicity; a third of the 9% 
developed toxicity before 3 months and the other two-thirds after 3 months35. Reasons for the 
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accelerated onset of toxicity associated with brainstem lesions remain to be determined but may 
be due to lack of compressibility in the surrounding space for edema when compared to the 
cerebral hemispheres. 
Consistent with previous reports suggesting that both melanoma and RCC are known to 
spontaneously result in intracranial hemorrhages 36,37, 4 of the 6 melanoma BSM toxicities and 1 
of the 3 renal cell carcinoma (RCC) toxicities were hemorrhages. Based on the above results of 
the 35 toxicities summarized in Table 3, development of toxicity occurs at a variety of 
prescription doses of SRS. The median prescription dose of cases with reported toxicity was 16 
Gy and two-thirds of the cases were accounted for by a prescription dose up to 18 Gy. It has 
previously been reported that higher doses lead to more toxicity but based on the data in Table 3 
it seems toxicity can occur at a wide range of doses 22. Patient level data on tumor volume or 
radiation dose was not available in all toxicity cases for this analysis. Thus, the impact of tumor 
volume and radiation dose on toxicity could not be analyzed on a larger scale in a location 
specific manner. 
Interestingly, only one toxicity in the medulla was reported. A large study reporting 44 
grade 3 and higher toxicities concluded that location did not predict toxicity 22. Location specific 
toxicity data was not available in this report and thus was not incorporated into the location 
analysis. Location specific treatment volumes and radiation dose are reported only on a small 
subset of patients and thus there is a possibility that treatment preferences and lesion 
characteristics based on location differ 6,16,21,28. Six case reports were excluded from the review 
that involved BSM treated via SRS, but none of the lesions in those reports were in the medulla 
38-43
. The higher prevalence of toxicity in pontine lesions is likely associated with the frequency 
of occurrence of BSM in the pons.  
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There are several limitations to this report. Given the design of this study, it is inherently 
limited by the quality of the reports included. For instance, the prescription dose was commonly 
reported as the ‘marginal dose’ with no reference of the isodose line to which the prescription 
dose was defined in the majority of the studies. Sadly, in retrospective studies planning details 
such as rapid dosage drop to the surrounding parenchyma are not easily reported and this could 
lead to variation in the data.  It should be noted that not all studies detail treatment or lesion 
characteristics of brainstem metastasis. It is also uncertain if the reports that do include specific 
details are representative of the broader series. This data also might not be representative of the 
percentage of patient the develop toxicity after SRS to BSM, since many patients might not 
survive long enough for toxicities to develop. Further investigations might provide more 
insight into treatment preferences and why/if medulla toxicities are truly rare.  
Conclusion 
In conclusion, for BSM treated via SRS, the median prescription doses vary from 13-
18 Gy, with a local control rate of 86.7 ± 5.9% and a rate of toxicity of 3.4 ± 2.9%. The most 
common site of BSM is the pons. The median time to toxicity is 3 months for BSM treated by 
SRS. The current literature reports that some BSM may be safely treated with a prescription dose 
of up to 18 Gy or more and that volume and location do not predict for toxicity. More research is 
needed to further clarify these trends. This data shows that no recipe for safe treatment of 
brainstem metastases does (yet) exist, but in most cases local tumor control can be achieved with 
acceptable toxicity. 
Funding- None 
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Figure Legend 
Figure 1: Flow Diagram 
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Table 1: Relevant nervous system specific toxicity grading for adverse events from NIH NCI 
CTCAE. 
Adverse 
Event 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
General Mild; 
asymptomatic or 
mild symptoms; 
clinical or 
diagnostic 
observations only; 
intervention not 
indicated. 
 
Moderate; 
minimal, local or 
noninvasive 
intervention 
indicated; limiting 
age-appropriate 
instrumental 
ADL. 
Severe or 
medically 
significant but not 
immediately life-
threatening; 
hospitalization or 
prolongation of 
hospitalization 
indicated; 
disabling; limiting 
self-care ADL. 
Life-threatening 
consequences; 
urgent 
intervention 
indicated. 
Death related to 
AE. 
Edema - - - Life-threatening 
consequences; 
urgent 
intervention 
indicated. 
 
Intracranial 
hemorrhage 
Asymptomatic; 
clinical or 
diagnostic 
observations only; 
intervention not 
indicated 
Moderate 
symptoms; 
medical 
intervention 
indicated 
Ventriculostomy, 
ICP monitoring, 
intraventricular 
thrombolysis, or 
operative 
intervention 
indicated 
Life-threatening 
consequences; 
urgent 
intervention 
indicated 
Death 
Central 
nervous 
system 
necrosis 
Asymptomatic; 
clinical or 
diagnostic 
observations only; 
intervention not 
indicated 
Moderate 
symptoms; 
corticosteroids 
indicated 
Severe symptoms; 
medical 
intervention 
indicated 
Life-threatening 
consequences; 
urgent 
intervention 
indicated 
Death 
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Table 2: Summary of BSM treated by SRS studies. 
Author Year Method Pts/Lesio
ns 
Location 
Mb/(MP)
/Po/(PM)
/Mu/(CP) 
Median 
Age 
(years) 
Median 
KPS 
Median 
Margin 
Dose 
(Gy) 
No of pts 
w/ 
WBRT  
Median 
Survival 
(months) 
Local 
Tumor 
Control 
Rate (%) 
Toxicity 
(%) 
Median 
Tumor 
Volume 
(cc) 
Huang 1999 GK 26/27 6/21/0 56a 80a 16 24/92% c 9 95 0 1.1 
Shuto 2003 GK 25/31 10/19/2 57.1a NR 13a 7/28%c 49 77.4 8 2.1a 
Fuentes 2006 GK 28/28 9/17/2 57.7a 80a 19.6a 6/21%c 12 92 NR 2.1a 
Yen 2006 GK 53/53 8/42/3 57.3a 80 18 21/40% 11 86.5 0 2.8a 
Hussain 2007 GK 22/25 9/12/4 60 90 16 3/14% 
(after) 
8.5 100 4.5 0.9 
Kased 2008 GK 42/44 7/31/6 55 90 16 24/57%c 9 77 9.5 0.3 
Lorenzoni 2009 GK 25/27 9/14/4 54a 90 20a 17/68%c 11.1 95 0 0.6a 
Samblas 2009 LINAC 28/30 8/20/2 52.9a NR 11.1a 27/96.4%
c
 
16.8a 96.4 NR 1.9a 
Koyfman 2010 GK 43/43 NR 59 80 15 34/79%c 5.8 85 0 0.4 
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Valery 2011 LINAC 30/30 9/16/5 57 80a 13.4 8/27% 10 79 0 2.8 
Kelly 2011 LINAC 24/24 10/13/1 57 80 13 23/96% 5.3 78.6 8.3 0.2 
Yoo 2011 GK 32/32 6/23/3 56.1a NR 15.9 NR 7.7a 87.5 3.1 1.5a 
Hatiboglu 2011 LINAC 60/60 15/39/6 61 90 15 15/25%c 4 76 3.3 1 
Lin 2012 LINAC 45/48 7/35/6 59.9a 80 14 21/44% 11.6 88 4.7 0.4 
Leeman 2012 LINAC 36/38 11/25/2 62 80 17 18/47% 3 93e 0 0.9 
Li 2012 GK 28/32 8/21/3 61 80 16 0/0% 9 90.6 3.6 0.8 
Kawabe 2012 GK 200/222 65/121/3
6 
64a 90 18 13/6.5% 6 81.8 0.5 0.2 
Sengoz 2013 GK 44/46 14/30/2 57 80 16 29/66%c 8 96 0 0.6 
Jung 2013 GK 32/32 9/18/5 50 NR 13 19/59%c 5.2 87.5 0 0.7 
Peterson 2014 GK 41/? NR 59 NR 17a 19/46% 4.4 91 2.4 0.7a 
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Kilburn 2014 GK 44/52 9/(3)/28/
4b 
57 80 18 25/57% 6 74 9.1 0.1 
Voong 2015 GK 74/77 11/60/6 59 90 16 43/58%c 3.9 94 8 0.1 
Liu 2015 CK 54/66 12/49/5 59 70 17.9f 34/51.5%
d
 
5 80 1.5 0.1 
Trifiletti 2015 GK 161/189 36/129/1
4/(10) 
60.5 80 18 83/51.6% 5.5 87.3 1.8 0.4 
Joshi 2016 GK 48/51 10/34/7 62 90 15 19/40% 7.6 89 4 0.1 
Trifiletti 
Int 
2016 GK 547/596 126/(44)/
345/(22)/
45/(14) 
61 90 16 266/49% 5.5 81.8 7.4 0.8 
Murray 2016 GK 44/48 5/(3)/29/(
5)/6 
58 NR 15 33/75%c 5.4 76.9 8.3 1.3 
Nakamura 2017 CK 20/26 4/18/4 69 90 16.4f 5/19%g 11.5 90 5 0.33 
Patel 2018 GK 14/19 3/13/3 56 85 17.5 6/42.8%c 17.2 87.5 0 0.04 
Total   1878/203
7 
436/(50)/
1222/(27
)/186/(24
) 
   48.4±19.
8% 
 86.7±5.9 3.4 ± 2.9  
Abbreviations: CK= Cyber Knife; CP= cerebellopontine angle; GK= Gamma Knife; LINAC= Linear Accelerator; Mb= Midbrain; 
MP= Pontomesencephalic junction, Mu= Medulla; NR= Not reported; Po= Pons, PM= pontomedullary junction 
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a The mean value is reported instead of the median.  
b Location of other 8 lesions not specified in report 
c Patients received WBRT either before or after with no specification in manuscript or it was unclear whether patients received WBRT 
before or after. 
d The number of lesions that received WBRT were reported, not number of patients.   
e This is the local tumor control rate at 6 months, the others are reported at 12 months.  
f Single Session Equivalent Dose  
gLesions receiving WBRT not patients 
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Table 3: Characteristics of the 35 detailed reports of toxicity in the literature. Note the number in 
parentheses after the characteristic is the number out of 35 that reported that specific detail.  
TOTAL 35 CASES RANGE MEDIAN/PERCENTAGE 
AGE (17) (YEARS) 30-73 59 
 
30-50 17.6% 
 
50-60 41.2% 
 
>60 41.2% 
GENDER (22) (M/F) 13/9 59%/41% 
HISTOLOGY (29)   
 
NSCLC 24.1% 
 
SCLC 3.4% 
 
Breast 13.8% 
 
Melanoma 24.1% 
 
RCC 10.3% 
 
Thyroid 3.4% 
 
Sarcoma 3.4% 
 
Colon 3.4% 
 
Ovarian 3.4% 
 
Unknown 10.3% 
LOCATION (34)   
 
Midbrain 23.5% 
 
Pons 73.5% 
 
Medulla 2.9% 
TUMOR VOLUME (29) (CC) 0.1-5.8 1.4cc 
 
0-1cc 41.4% 
 
1-2cc 34.5% 
 
>2cc 24.1% 
MARGIN DOSE (31) (GY) 12 to 20 16 
 
12 -15.9 35.5% 
 
16-17.9 22.6% 
 
≥18 41.9% 
WBRT (15)   
 
Yes 33.3% 
 
No 66.7% 
TOXICITY (27)   
 
Hemorrhage 29.6% 
 
Radionecrosis 29.6% 
 
Edema 25.9% 
 
Edema and RN 7.4% 
 
RN and Hmg 3.7% 
 
Unkowna  3.7% 
TIME TO TOXICITY FROM 0-18 months 3 months 
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SRS (30) (MOS) 
 
≤3 months 60.0% 
 
≤6 months 83.3% 
 
≤9 months 93.3% 
 
≤18 months 100% 
LOCAL FAILURE (16)   
 
Yes 18.8% 
 
No 81.2% 
DOSE BY LOCATION (31)   
MIDBRAIN (6)  15 Gy 
 
12-15.9 Gy 50.0% 
 
16-17.9 Gy 16.7% 
 
≥18 Gy 33.3% 
PONS (24)  16.3 Gy 
 
12-15.9 Gy 25.0% 
 
16-17.9 Gy 29.2% 
 
MEDULLA (1) 
≥18 Gy 45.8% 
 15 Gy 100% 
TUMOR VOLUME BY 
LOCATION (29) 
  
MIDBRAIN (6)  0.9 cc 
 
0-1cc 50% 
 
1-2cc 33.3% 
 
>2cc 16.7% 
PONS (22)   1.3 cc 
 
0-1cc 40.9% 
 
1-2cc 31.8% 
 
MEDULLA (1) 
>2cc 27.3% 
 1.3cc 100% 
Abbreviations: Hmg=Hemorrhage; NSCLC= Non-small cell lung cancer; RCC= Renal cell 
carcinoma; RN=Radionecrosis; SCLC= Small cell lung cancer 
a Unknown due to no imaging.  
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Figure 1: Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aTwo reports were discounted in the quantitative synthesis because one was a review paper and 
the other was a matched cohort analysis that included the same cohort of patients as another 
report already included in the quantitative synthesis. 
bMost of the case reports were not BSM, only 6 out of the 16 were BSM treated by SRS.  
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Records after duplicates removed 
(n = 101) 
Records screened 
(n = 31) 
Records excluded 
(n = 70)  
Brain Metastases and/or 
Primary Tumors (51) 
Non-metastases (2) 
Case Reports (16)
b
 
No Abstract Available (1) 
 
Full-text articles assessed 
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(n = 31) 
Full-text articles excluded, 
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Additional records 
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sources (OVID) 
(n = 0) 
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• For BSM treated via SRS, the median prescription doses vary from 13-18 Gy 
• For BSM treated via SRS the local control rate is 86.7 ± 5.9%  
• For BSM treated via SRS the rate of grade 3 or greater toxicity is 3.4 ± 2.9%.  
• The most common site of BSM is the pons.  
• The median time to toxicity is 3 months for BSM treated by SRS.  
• Volume and location do not predict for toxicity for BSM treated via SRS.  
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BSM – Brainstem Metastases 
SRS – Stereotactic Radiosurgery 
KPS – Karnofsky Performance Status 
WBRT – Whole Brain Radiation Therapy 
GK – Gamma Knife 
CK – Cyber Knife 
LINAC – Linear Accelerator  
CPA – Cerebellopontine Angle 
Gy – Gray 
NIH – National Institute of Health 
NCI – National Cancer Institute 
CTCAE – Common Terminology Criteria for Adverse Events 
Hmg - Hemorrhage 
NSCLC - Non-small cell lung cancer 
RCC - Renal cell carcinoma 
RN - Radionecrosis 
SCLC - Small cell lung cancer 
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